DGIdb - VINORELBINE Drug Record

VINORELBINE chembl:CHEMBL553025 ApprovedAntineoplasticImmunotherapy

Alternate Names:

VINORELBINE
VINORELBINE BASE

Drug Info:

Year of Approval	1994
Drug Class	antineoplastic agents
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent

(5 More Sources)

Publications:

Parrino B et al., 2015, Water-soluble isoindolo[2,1-a]quinoxalin-6-imines: in vitro antiproliferative activity and molecular mechanism(s) of action., Eur J Med Chem
Sun et al., 2009, Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients., Lung Cancer
Rodler et al., 2016, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer., Clin. Cancer Res.
Quinn et al., 2003, BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis., Cancer Res.
Sève et al., 2010, [Class III beta tubulin expression in nonsmall cell lung cancer]., Rev Mal Respir
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Chang et al., 1995, Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer., Semin. Oncol.
Kruczynski et al., 1998, Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid., Biochem. Pharmacol.
Ferrario et al., 2016, Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer., PLoS ONE
André et al., 2014, Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial., Lancet Oncol.
Liu et al., 2001, Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells., Br. J. Cancer
Bell et al., 2016, SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer., Clin. Cancer Res.
Klotz et al., 2012, The microtubule poison vinorelbine kills cells independently of mitotic arrest and targets cells lacking the APC tumour suppressor more effectively., J. Cell. Sci.
Qian J et al., 2012, Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment., Chest
Vilmar et al., 2013, Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial., Ann. Oncol.
Dong et al., 2014, Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression., PLoS ONE

VINORELBINE SMARCA4

Interaction Score: 0.68

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26671993

Sources:
CIViC
VINORELBINE RRM1

Interaction Score: 0.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23038758 24647522

Sources:
CIViC
VINORELBINE XRCC1

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19157633

Sources:
CIViC
VINORELBINE TUBB

Interaction Score: 0.33

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

PMIDs:
25768699 20403547 17016423 17139284 7740336 9515574

Sources:
DTC
VINORELBINE APC

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colon cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
22399804

Sources:
JAX-CKB
VINORELBINE CASP7

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22441531

Sources:
PharmGKB
VINORELBINE TUBB4A

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25768699

Sources:
DTC
VINORELBINE TUBA3C

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25768699

Sources:
DTC
VINORELBINE TUBB2A

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name vinorelbine,Navelbine

Novel drug target Established target

PMIDs:
25768699

Sources:
DTC TdgClinicalTrial TEND
VINORELBINE BRCA2

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cisplatin + Veliparib + Vinorelbine

Indication/Tumor Type Her2-receptor negative breast cancer

Response Type predicted – sensitive

PMIDs:
26801247

Sources:
JAX-CKB
VINORELBINE TUB

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
VINORELBINE TUBA1B

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25768699

Sources:
DTC
VINORELBINE TUBB8

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25768699

Sources:
DTC
VINORELBINE TUBB2B

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25768699

Sources:
DTC
VINORELBINE TUBB6

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25768699

Sources:
DTC
VINORELBINE TUBA3D

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25768699

Sources:
DTC
VINORELBINE TUBA4A

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25768699

Sources:
DTC
VINORELBINE TUBA1C

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25768699

Sources:
DTC
VINORELBINE TUBA3E

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25768699

Sources:
DTC
VINORELBINE TUBB3

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25768699

Sources:
DTC
VINORELBINE TUBA1A

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25768699

Sources:
DTC
VINORELBINE TUBB4B

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25768699

Sources:
DTC
VINORELBINE BAX

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11720482

Sources:
NCI
VINORELBINE BRCA1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase I

Response Type sensitive

PMIDs:
26801247 14559807

Sources:
JAX-CKB NCI
VINORELBINE TUBB1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25768699

Sources:
DTC
VINORELBINE ERBB2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Phase Ib/II

Response Type predicted – sensitive

Indication/Tumor Type Her2-receptor negative breast cancer

PMIDs:
27992451 24742739

Sources:
JAX-CKB

TEND: VINORELBINE
- Version: 01-August-2011
Alternate Names:

VINORELBINE Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 1994

Publications:
TdgClinicalTrial: VINORELBINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: VINORELBINE

Version: 14-September-2017

Alternate Names:

C1275 NCI drug code

Drug Info:

Publications:

Quinn et al., 2003, BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis., Cancer Res.

Liu et al., 2001, Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells., Br. J. Cancer

DTC: VINORELBINE BASE
- Version: 02-September-2020
Alternate Names:

CHEMBL553025 ChEMBL Drug ID

Drug Info:

Publications:

Parrino B et al., 2015, Water-soluble isoindolo[2,1-a]quinoxalin-6-imines: in vitro antiproliferative activity and molecular mechanism(s) of action., Eur J Med Chem
PharmGKB: vinorelbine
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Qian J et al., 2012, Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment., Chest

JAX-CKB: Vinorelbine

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Rodler et al., 2016, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer., Clin. Cancer Res.

Ferrario et al., 2016, Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer., PLoS ONE

André et al., 2014, Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial., Lancet Oncol.

CIViC: VINORELBINE

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Bell et al., 2016, SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer., Clin. Cancer Res.

Vilmar et al., 2013, Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial., Ann. Oncol.

Dong et al., 2014, Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression., PLoS ONE

TTD: Vinorelbine
- Version: 2020.06.01
Alternate Names:

D01HTL TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL553025
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Indication/Tumor Type	colon cancer
Response Type	sensitive
Approval Status	Preclinical

Trial Name	vinorelbine,Navelbine
Novel drug target	Established target

combination therapy	Cisplatin + Veliparib + Vinorelbine
Indication/Tumor Type	Her2-receptor negative breast cancer
Response Type	predicted – sensitive

Evidence Type	Actionable
Approval Status	Phase I
Response Type	sensitive

Approval Status	Phase Ib/II
Response Type	predicted – sensitive
Indication/Tumor Type	Her2-receptor negative breast cancer

antagonist (inhibitory)
inhibitor (inhibitory)

VINORELBINE Drug Record

VINORELBINE chembl:CHEMBL553025 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26671993

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23038758 24647522

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19157633

Sources: CIViC

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info:

PMIDs: 25768699 20403547 17016423 17139284 7740336 9515574

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colon cancer Response Type sensitive Approval Status Preclinical

PMIDs: 22399804

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22441531

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25768699

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25768699

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: Trial Name vinorelbine,Navelbine Novel drug target Established target

PMIDs: 25768699

Sources: DTC TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Cisplatin + Veliparib + Vinorelbine Indication/Tumor Type Her2-receptor negative breast cancer Response Type predicted – sensitive

PMIDs: 26801247

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25768699

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25768699

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25768699

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25768699

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25768699

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25768699

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25768699

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25768699

Interaction Types & Directionality:

n/a

PMIDs:
26671993

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
23038758 24647522

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
19157633

Sources:
CIViC

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

PMIDs:
25768699 20403547 17016423 17139284 7740336 9515574

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colon cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
22399804

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
22441531

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25768699

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
25768699

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name vinorelbine,Navelbine

Novel drug target Established target

PMIDs:
25768699

Sources:
DTC TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cisplatin + Veliparib + Vinorelbine

Indication/Tumor Type Her2-receptor negative breast cancer

Response Type predicted – sensitive

PMIDs:
26801247

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
25768699

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
25768699

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
25768699

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
25768699

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
25768699

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
25768699

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
25768699

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
25768699

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
25768699

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
25768699

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
25768699

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
11720482

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase I

Response Type sensitive

PMIDs:
26801247 14559807

Sources:
JAX-CKB NCI

Interaction Types & Directionality:

n/a

PMIDs:
25768699

Sources:
DTC

Interaction Types & Directionality:

n/a